TÜBINGEN, Germany – October 3, 2013

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on Messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac’s RNActive® technology.

RNActive® vaccines, based on CureVac‘s technology platform, have already demonstrated effectiveness and safety in several clinical trials. CureVac’s preclinical influenza studies, which were published in Nature Biotechnology in December 2012, have formed an important basis for this collaboration.

Under the terms of the collaboration, CureVac will develop optimized RNActive® vaccines based on Crucell’s proprietary antigen sequences which will be tested in various models.

Additional details of the collaboration were not disclosed.

About RNActive®

CureVac is combining both the antigenic and adjuvant properties of mRNAs to develop novel and effective mRNA vaccines. RNActive® vaccines are comprised of modified and formulated mRNA with three distinct features: The mRNA vaccines are translated into the target antigens, and the formulation and modifications lead to translatability ensuring (1) strong antigen expression, (2) increased stability and (3) enhanced immune-stimulatory activity. Furthermore the RNActive® technology allows a faster generation of vaccines than the conventional methods.

Media Contacts

Dr. Martina Schwarzkopf
Russo Partners, New York
T +1 (212) 845 4292
M +1 (347) 591 8785
T +1 (212) 845 4251